GoHealth Urgent Care

gohealthuc.com

GoHealth Urgent Care is one of the country's fastest-growing and largest urgent care providers. At GoHealth Urgent Care, we place the needs of our patients first by providing an effortless patient experience, a welcoming culture of care and seamless integration with market-leading health systems and our communities. GoHealth Urgent Care operates 80 urgent care centers in the New York and Portland, Oregon, metropolitan areas, the San Francisco Bay Area, Hartford, Connecticut, and will soon open urgent care centers in multiple Midwest markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

XTALPI PARTNERS WITH EXCELRA FOR GOSTAR TO ENHANCE ITS INTELLIGENT DIGITAL DRUG DISCOVERY AND DEVELOPMENT PLATFORM

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

news image

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data...

Read More

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

news image

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

news image

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More

VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER

Business Wire | February 17, 2020

news image

Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, h...

Read More
news image

Research

XTALPI PARTNERS WITH EXCELRA FOR GOSTAR TO ENHANCE ITS INTELLIGENT DIGITAL DRUG DISCOVERY AND DEVELOPMENT PLATFORM

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data...

Read More
news image

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More
news image

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More
news image

VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER

Business Wire | February 17, 2020

Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, h...

Read More